Related references
Note: Only part of the references are listed.Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II
Christopher S. Lunde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In vitro activity of telavancin against resistant gram-positive bacteria
Kevin M. Krause et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Pneumonia caused by methicillin-resistant Staphylococcus aureus
Ethan Rubinstein et al.
CLINICAL INFECTIOUS DISEASES (2008)
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia
Peter E. Pertel et al.
CLINICAL INFECTIOUS DISEASES (2008)
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics
Mark H. Gotfried et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
A randomized trial of diagnostic techniques for ventilator-associated pneumonia
Daren Heyland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus
Kimberly D. Leuthner et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Epidemiology and outcomes of health-care-associated pneumonia - Results from a large US database of culture-positive pneumonia
MH Kollef et al.
CHEST (2005)
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus
DL Higgins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
[Anonymous]
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia -: The subtleties of subgroup analyses
JH Powers et al.
CHEST (2004)
Prevention of hospital-associated pneumonia and ventilator-associated pneumonia
MH Kollef
CRITICAL CARE MEDICINE (2004)
Drotrecogin alfa (activated) improves in-hospital and 90-day survival in patients with severe sepsis and community-acquired pneumonia
RG Wunderink et al.
CHEST (2003)
In vitro activity of TD-6424 against Staphylococcus aureus
JL Pace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Linezolid vs vancomycin - Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia
RG Wunderink et al.
CHEST (2003)
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
E Rubinstein et al.
CLINICAL INFECTIOUS DISEASES (2001)
Nosocomial infections in combined medical-surgical intensive care units in the United States
MJ Richards et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2000)
Share Paper
